SRR2016935
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.460
- IL6_JAK_STAT3_SIGNALING+0.440
- COMPLEMENT+0.410
- INFLAMMATORY_RESPONSE+0.410
- COAGULATION+0.330
- IL2_STAT5_SIGNALING+0.310
- INTERFERON_GAMMA_RESPONSE+0.230
- TNFA_SIGNALING_VIA_NFKB+0.230
- ANGIOGENESIS+0.210
- BILE_ACID_METABOLISM+0.210
Top 10 suppressed
- MYC_TARGETS_V1-0.600
- MYC_TARGETS_V2-0.530
- OXIDATIVE_PHOSPHORYLATION-0.530
- E2F_TARGETS-0.450
- G2M_CHECKPOINT-0.420
- GLYCOLYSIS-0.360
- DNA_REPAIR-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.290
- ESTROGEN_RESPONSE_LATE-0.280
- WNT_BETA_CATENIN_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518268 | — | A | 0.863 |
| 2 | TCGA-55-8208-01A-11R-2241-07 | — | cohortMD2 | 0.848 |
| 3 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.846 |
| 4 | SRR10899975 | — | — | 0.842 |
| 5 | TCGA-MP-A4TJ-01A-51R-A262-07 | — | cohortA1 | 0.831 |
| 6 | TCGA-97-A4LX-01A-11R-A24X-07 | — | cohortA1 | 0.831 |
| 7 | TCGA-L4-A4E6-01A-11R-A24H-07 | — | cohortA1 | 0.829 |
| 8 | R132 | — | — | 0.827 |
| 9 | C3L-03976 | — | cohortMD2 | 0.827 |
| 10 | d24acd56-d148-487c-8d44-b303a68eb9d2 | — | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.030 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |